Inhaled amikacin vs placebo for breathing tube infection
Part of Infections, Lungs & breathing clinical trials.
This trial tests if an inhaled antibiotic (amikacin) can treat an infection in the breathing tube (ventilator-associated tracheobronchitis) better than a placebo. You may qualify if you are on a ventilator and have this type of infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Admitted to an intensive care unit
- On a breathing machine (ventilator) for more than 48 hours
- First time having a ventilator-associated breathing tube infection
- Must be covered by French health insurance
- Not allergic to amikacin or similar antibiotics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an “antibiotic stewardship” approach—choosing and adjusting antibiotics in a smarter way—for a first episode of pneumonia in patients on a breathing machine. It may help ensure the right antibiotics are used at the right time, while avoiding unnecessary or overly broad treatment.
This trial studies whether changing immune cells in the lungs (using a procedure called MiniBAL) can improve outcomes in adults who are critically ill and on a breathing tube. It may help doctors better manage acute lung injury by targeting inflammation early in the ICU stay.
This trial tests whether a nebulized (inhaled) antibiotic called colistin can prevent lung infections in children who have been on a breathing machine for more than 48 hours. If your child is eligible, the treatment may help reduce the risk of ventilator-associated pneumonia.
This trial tests whether inhaling an antibiotic called amikacin can prevent ventilator-associated pneumonia in patients with severe liver disease (cirrhosis) who are on a breathing machine. If you or your loved one is in the ICU with liver issues and needs a ventilator, this study may help reduce the risk of a serious lung infection.
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
This trial tests if giving antibiotics based on a patient's unique gut bacteria can prevent pneumonia in people who are on a breathing machine (ventilator) in the intensive care unit (ICU). It aims to see if this personalized approach is more effective than standard care.
Hear when a new Ventilator Associated Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.